End-stage kidney disease patients with severe coronavirus disease: clinical characteristics, biological data, and mortality in nephrology unit, short communication.
COVID-19
dialysis
end-stage kidney disease
lung damage
mortality
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
25
10
2022
accepted:
10
06
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Patients suffering from end-stage kidney disease (ESKD) are particularly vulnerable to SARS-CoV-2 infection, and their risk of death is higher than for the general population. The objective was to determine the epidemiologic profile at admission and mortality among patients presenting EKSD with severe coronavirus disease (COVID-19). A retrospective study was conducted in the Nephrology unit between October 2020 and February 2022. Were included all adult patients who presented ESKD on dialysis, or not on dialysis with an estimated glomerular filtration rate less than or equal to 15 ml/min/1.73 m Sixty-five patients' data were collected. The mean age was 58.9 ±16.7 years and 60% were males. Hypertension arterial and diabetes observed in 75% and 56.3% of cases, respectively. 52.3% were on haemodialysis, 4.6% were on peritoneal dialysis and 43.1% not were on dialysis. 94% of the patients were symptomatic of COVID-19, dominated by dyspnoea (87.5%), cough (65.6%), and fever (58.5%). More than half of patients (58.5%) showed signs of gravity and 62% required oxygen therapy. According to thoracic scan, 72.3% were classified COVID-19 Raw Data System 5 and 6. Most patients had severe anaemia (58.5%), lymphopenia (81.3%), and high levels of C-reactive protein (54%), D-Dimer (93.6%) and ferritin (91.2%). 38.5% of patients presented complications of whom 60% were transferred to ICU. Mortality was observed in 8% of cases. Rigorous monitoring is necessary for patients in ESKD, particularly those with comorbidities, to reduce the risk of severe form of COVID-19.
Identifiants
pubmed: 37554878
doi: 10.1097/MS9.0000000000000962
pii: AMSU-D-22-02560
pmc: PMC10406044
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4182-4186Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Nephrol. 2020 Aug;33(4):725-736
pubmed: 32621109
BMC Nephrol. 2023 Mar 22;24(1):67
pubmed: 36949428
Nephrol Dial Transplant. 2020 Dec 4;35(12):2083-2095
pubmed: 33275763
Kidney Int Rep. 2022 Mar;7(3):397-409
pubmed: 34957349
Clin Kidney J. 2021 Feb 05;14(3):805-813
pubmed: 33777363
J Nephrol. 2021 Feb;34(1):15-17
pubmed: 33387339
J Am Soc Nephrol. 2020 Jul;31(7):1409-1415
pubmed: 32467113
Kidney Med. 2021 Jul-Aug;3(4):619-634
pubmed: 34007963
Medwave. 2022 Dec 29;22(11):e2562
pubmed: 36583875
BMC Nephrol. 2021 Feb 27;22(1):73
pubmed: 33639881
Clin Kidney J. 2020 Jun 22;13(3):334-339
pubmed: 32695323
J Nephrol. 2023 Apr;36(3):601-603
pubmed: 37014614
Healthcare (Basel). 2021 Jan 05;9(1):
pubmed: 33466527
J Am Soc Nephrol. 2021 Jun 1;32(6):1444-1453
pubmed: 33833076